State of Parkinson's Research, June 2026

A dated, reproducible monthly snapshot of the Parkinson's clinical trial landscape, archived 2026-06-16 so the figures stay citable over time.

Headline Figures

• Recruiting trials tracked: 506
• New this month: 13
• Phase 3 trials: 11
• Countries with trial sites: 44
• Interventional: 355
• Observational: 151
• Average minimum age: 31 years
• Total ever opened (lifetime, survivorship-immune): 0

Takeaways

• As of June 2026, 506 Parkinson's trials are recruiting across 44 countries.
• The most common research focus among recruiting trials is Alpha-synuclein (3 trials).

Top Countries

• United States: 168 recruiting trials
• China: 61 recruiting trials
• Italy: 42 recruiting trials
• France: 30 recruiting trials
• United Kingdom: 30 recruiting trials
• Turkey: 29 recruiting trials
• Germany: 27 recruiting trials
• Canada: 26 recruiting trials
• Netherlands: 21 recruiting trials
• Spain: 19 recruiting trials

Top Drug Classes

• alpha-syn: 3 trials
• DBS: 2 trials
• monoclonal-antibody: 2 trials
• GBA: 1 trials
• focused-ultrasound: 1 trials
• gene-therapy: 1 trials

Top Sponsors

• University of Minnesota: 12 trials
• VA Office of Research and Development: 9 trials
• Xiangya Hospital of Central South University: 7 trials
• University of Alabama at Birmingham: 6 trials
• Beijing Tiantan Hospital: 6 trials
• University of Exeter: 5 trials
• University of British Columbia: 5 trials
• Insel Gruppe AG, University Hospital Bern: 5 trials
• Radboud University Medical Center: 5 trials
• AbbVie: 5 trials

See the live State of Parkinson's Research dashboard for the current interactive picture.